ClinicalTrials.gg
RecruitingNCT06974929Updated Jun 12, 2026

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

A Phase 1/2 interventional study of HRS-6209 Capsules and Letrozole Tablets in Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 18 open to participants now, 27 under way, 12 of them phase 3. Breast Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
35th of 53
80 · median 150
Started
2025
with 5 others
Phase 1/2
10 of 53
8 open now
Primary completion
2026-12
later than 12 of 26 live
Registered
41st of 53
by date

Among the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 35th largest by planned enrollment, is one of 6 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 12 of the 26 other live ones, and was the 41st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18-75 years.
  2. performance status 0-1.
  3. Menopausal status.
  4. Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration.
  5. At baseline, there must be at least one measurable, extracranial lesion that meets v1.1 criteria.
  6. Expected survival > 3 months.
  7. Women of must agree to use highly effective measures during the study treatment and for 6 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days prior to study enrollment and must not be breastfeeding.
  8. Voluntarily agree to participate in this clinical trial, willing and able to comply with the study visits and procedures, understand the study procedures, and have signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic visceral and other conditions, and the researcher judged that endocrine therapy was not suitable for use.
  2. History of clinically serious cardiovascular disease.
  3. The examination was abnormal.
  4. Patients with endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.
  5. The subjects were in acute infection or active tuberculosis and needed drug treatment.
  6. The patients received surgery, chemotherapy, immunotherapy and macromolecular targeted therapy within 4 weeks before the first medication.
  7. Pregnant and lactating women, or intending to become pregnant during the study.
  8. There was a clear history of neurological or mental disorders and the subjects had a history of psychotropic drug abuse or drug abuse.
  9. In the course of this study, it is expected to receive other anti-tumor treatments or drugs.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    HRS-6209 in Combination with Letrozole Group

    Drug: HRS-6209 Capsules · Drug: Letrozole Tablets

  • Experimental
    HRS-6209 combined with Letrozole and HRS-2189 Group

    Drug: HRS-6209 Capsules · Drug: Letrozole Tablets · Drug: HRS-2189 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: 28 days after the first dose.

  2. Maximum tolerated dose (MTD)

    Time frame: 28 days after the first dose.

  3. Recommended phase II dose (RP2D)

    Time frame: 28 days after the first dose.

  4. Adverse events (AEs)

    Time frame: About 1 year.

  5. Serious adverse events (SAEs)

    Time frame: About 1 year.

  6. Objective response rate (ORR)

    Time frame: About 1 year.

Secondary outcomes

  1. Best overall response (BOR)

    Time frame: About 1 year.

  2. Duration of response (DoR)

    Time frame: About 1 year.

  3. Clinical benefit rate (CBR)

    Time frame: About 1 year.

  4. Progression-free survival (PFS)

    Time frame: About 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 19 months is below that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
May 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974929
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 12, 2026

Study contacts

Xiaoyu Zhu
Contact
Xiaoyu.zhu@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-6209

Start the discussion